News

The Perrigo product is a proton pump inhibitor and antacid indicated for the treatment of frequent heartburn. Perrigo has also provided prior notice of this filing to Schering-Plough

As per the extended agreement, Wyeth’s commercialisation efforts in the US is expected to continue through 31 December 2010, and may be extended at Progenics’ option to 31

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition OctoPlus offers its clients drug delivery technologies for the development of

According to Progenika Biopharma, the diagnostic test rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD) and has been developed under an agreement with Amsterdam Molecular

Novartis said that the CHMP recommendation will serve as the basis for the European Commission making its licensing decision of the Aflunov product. Based on the CHMP approval,

Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. The Phase III study assessed Zibotentan 10mg added to standard of care treatment in

Bayer claimed that Beyaz is the first OC approved to raise folate levels, in women who choose an OC for birth control, for the purpose of reducing the

According to the CHMP, the benefits from using the drug to treat MS did not justify its risks. Recently, Merck’s MS pill got Austrailian and Russian approval and

In the Phase 1 trial Stedivaze was administered to patients with mild to moderate asthma as a single IV bolus, the same as utilized in the ongoing Phase